444805-28-1

Basic information

• Product Name: CMX 001
• Synonyms: Brincidofovir (CMX001);Brincidofovir;CMX001(Brincidofovir);(S)-[2-(4-amino-2-oxo-1,2-dihydro-1-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methylphosphonic acid 3-(hexadecyloxy)propyl monoester;[[(S)-2-(4-Amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid mono[3-(hexadecyloxy)propyl] ester;CMX 001;HDP-cidofovir;Hexadecyloxypropyl-cidofovir
• CAS NO: 444805-28-1
• Molecular Formula: C27H52N3O7P
• Molecular Weight: 561.691441
• Mol File: 444805-28-1.mol

Chemical Properties

• Boiling Point: 688.6±65.0 °C(Predicted)
• Appearance: /
• Density: 1.17±0.1 g/cm3(Predicted)
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• Solubility: DMSO (Slightly, Sonicated), Ethanol (Slightly, Heated, Sonicated), Methanol (Sli
• PKA: 2.40±0.10(Predicted)
• Stability: Hygroscopic
• CAS DataBase Reference: CMX 001(CAS DataBase Reference)
• NIST Chemistry Reference: CMX 001(444805-28-1)
• EPA Substance Registry System: CMX 001(444805-28-1)

Safety Data

• Hazardous Substances Data: 444805-28-1(Hazardous Substances Data)

Usage

Uses

Used in Antiviral Applications:
CMX 001 is used as an antiviral inhibitor for preventing the replication of BK polyomavirus in primary human urothelial cells. Its effectiveness in inhibiting viral replication makes it a valuable asset in the fight against viral infections.
Used in Cancer Treatment:
In the field of oncology, CMX 001 serves as a cytostatic and cytotoxic agent. It works by inhibiting the growth and proliferation of cancer cells, making it a potential candidate for cancer treatment. Its cytotoxic properties allow it to target and destroy cancer cells, while its cytostatic effects prevent them from dividing and spreading.
Used in Pharmaceutical Industry:
CMX 001 is used as an active pharmaceutical ingredient for the development of new drugs and therapies. Its diverse applications in antiviral and cancer treatment make it a promising candidate for further research and development in the pharmaceutical industry.
Used in Drug Delivery Systems:
CMX 001 can also be utilized in the development of novel drug delivery systems. These systems aim to improve the bioavailability, delivery, and therapeutic outcomes of the compound by employing various organic and metallic nanoparticles as carriers for CMX 001.

Biological Activity

cmx001 is a broad spectrum antiviral agent [1].cmx001 has been reported to be active in vitro against a broad range of viruses from all five families of dsdna viruses infecting human with ec50 values of 0.02μm, 0.0004μm, 17μm , 0.045μm and 0.07μm for adenovirus, herpesvirus, papillomavirus, polyomavirus and orthopoxvirus, respectively. in addition, cmx001 has been revealed to arrest disease progression by inhibiting viral dna replication and thereby reducing viral burden. apart from these, initial studies has been demonstrated the efficacy of cmx001 for pre-exposure and post-exposure prophylaxis in mouse, rabbit, cynomolgus monkeys and human [1].

references

[1]lanier r1, trost l, tippin t, lampert b, robertson a, foster s, rose m, painter w, o'mahony r, almond m, painter g.development of cmx001 for the treatment of poxvirus infections. viruses. 2010 dec; 2(12):2740-2762.

Upstream product

• 36653-82-4 1-Hexadecanol 
• 20779-14-0 methanesulfonic acid hexadecyl ester 
• 864068-45-1 {[3-(hexadecyloxy)propoxy](hydroxy)phosphoryl}methyl tosylate 
• 864068-43-9 1-(S)-[3-trityloxy-2-hydroxypropyl]-N⁴-monomethoxytritylcytosine 
• 912635-37-1 cyclic cidofovir DCMC salt 
• 132336-30-2 (S)-N-1-[(2-hydroxy-3-triphenylmethoxy)propyl]cytosine 
• 1362039-08-4 phosphonic acid [[(S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)-2-(triphenylmethoxy)ethyl]methyl]mono[3-(hexadecyloxy)propyl]ester 
• 864068-46-2 N₄-monomethoxytrityl-O₃'-trityl-cidofovir, hexadecyloxypropyl ester 
• 23377-40-4 3-hexadecyloxy-1-propanol 
• 113852-37-2 cidofovir 
• 127757-45-3 cyclic cidofovir 
• 126614-26-4 1-(hexadecyloxy)-3-bromopropane 
• 343248-25-9 1-O-hexadecyloxypropyl cyclic cidofovir 

Relevant articles and documents

Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir

The nucleotide phosphonates cidofovir (CDV) and cyclic cidofovir (cCDV) are potent antiviral compounds when administered parenterally but are not well absorbed orally. These compounds have been reported to have activity against orthopoxvirus replication i

Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro

The incidence of cytomegalovirus (CMV) retinitis is declining in AIDS patients but remains a significant clinical problem in patients with organ transplants and bone marrow transplants. Prophylaxis with ganciclovir (GCV) or valganciclovir reduces the incidence of CMV disease but may lead to the emergence of drug-resistant virus with mutations in the UL97 or UL54 gene. It would be useful to have other types of oral therapy for CMV disease. We synthesized hexadecyloxypropyl and octadecyloxyethyl derivatives of cyclic cidofovir (cCDV) and cidofovir (CDV) and found that these novel analogs had 2.5- to 4-log increases in antiviral activity against CMV compared to the activities of unmodified CDV and cCDV. Multiple-log increases in activity were noted against laboratory CMV strains and various CMV clinical isolates including GCV-resistant strains with mutations in the UL97 and UL54 genes. Preliminary cell studies suggest that the increase in antiviral activity may be partially explained by a much greater cell penetration of the novel analogs. 1-O-Hexadecyloxypropyl-CDV, 1-O-octadecyloxyethyl-CDV, and their corresponding cCDV analogs are worthy of further preclinical evaluation for treatment and prevention of CMV and herpes simplex virus infections in humans.

Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof

The disclosure describes methods of synthesis of phosphonate ester compounds. The methods according to the disclosure allow for large-scale preparation of phosphonate ester compounds having high purity and stability. Also disclosed are morphic forms of ph

Phosphonate Ester Derivatives and Methods of Synthesis Thereof

The disclosure describes methods of synthesis of phosphonate ester derivatives. Preferred methods according to the disclosure allow for large-scale preparation of phosphonate ester compounds having high purity. In some embodiments, preferred methods accor

COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF POXVIRUS INFECTIONS

The present application provides methods and compositions for combination therapy with antiviral compounds for the treatment of poxvirus infections, such as orthopox virus infections. In one embodiment, a method of treatment of a poxvirus infection is provided that comprises administering to a host in need thereof cidofovir, cyclic cidofovir, or a salt, ester, or prodrug thereof in combination or alternation with at least a second anti-poxvirus agent. The second anti-poxvirus agent is, for example, a biologic, such as a pegylated interferon.

COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER MEDICAL DISORDERS

The present application provides methods and compositions for improving the bioavailability of a lipid-containing antiviral compound, and in particular, an antiviral lipid-containing compound. In one embodiment, pharmaceutically acceptable compositions ar

METHODS FOR PREPARATION OF NUCLEOSIDE PHOSPHONATE ESTERS

A process is provided for the preparation of lipophilic monoesters of formula (3) and their stereoisomers. The process includes the steps of esterification of a phosphonate with a lipophilic alcohol, then allowing the resultant product to react with a sui

PHOSPHONATE COMPOUNDS

The present invention relates to phosphonate compounds, compositions containing them, processes for obtaining them, and their use for treating a variety of medical disorders, e.g., osteoporosis and other disorders of bone metabolism, cancer, viral infections, and the like.